Brief: Abbisko Cayman's New Drug Application For Pimicotinib Formally Accepted By U.S. FDA
13/01/2026 10:09
Jan 13 (Reuters) - Abbisko Cayman Ltd 2256.HK: UNIT'S NEW DRUG APPLICATION FOR COLONY-STIMULATING FACTOR 1 RECEPTOR INHIBITOR PIMICOTINIB FORMALLY ACCEPTED BY US FDA Further company coverage: 2256.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Abbisko Cayman
See all newsHK-listed Abbisko climbs most in 12 weeks on Eli Lilly tie-up
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly (updated)
Brief: Abbisko Therapeutics Deepens R+D- Collaboration With Lilly
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly
Brief: Abbisko Therapeutics Enters Strategic Research Collaboration And License Agreement With Eli Lilly